Trial Profile

A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin and EU Approved Avastin in Healthy Male Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 11 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary)
Indications Breast cancer; Cancer; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Renal cell carcinoma
Focus Pharmacokinetics
Sponsors mAbxience

09 Aug 2021 Result (n=114) assessing pharmacokinetic equivalence in healthy male volunteers between MB02 and the reference bevacizumab, as well as comparable safety and immunogenicity profile, published in the British Journal of Clinical Pharmacology.
07 Sep 2020 Status changed from active, no longer recruiting to completed.
27 Jan 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com